Harvey is a Partner focusing on the Life Sciences and Chemistry sectors. With over 25 years’ experience at first instance and appellate level, Harvey is recognised as one of the leading attorneys and advocates in contentious proceedings before the EPO and is a respected strategist and formidable opponent. IAM Patent 1000 comments that Adams is “an excellent attorney who is well recognised and respected in opposition proceedings at the EPO. He remains cool and collected under pressure to deliver favourable results in critical situations.” (IAM Patent 1000, 2024). He is also recognised by IAM in its 2026 Global Leaders guide.
He brings a wealth of knowledge and insight to any contentious matter and has therefore been entrusted with the defence of many important patents for landmark drugs, especially in the context of parallel or anticipated ANDA litigation. In addition to his work in the contentious arena, Harvey is adept at navigating FTO issues and devising prosecution strategies to maximise the strength and reach of clients’ IP. Harvey has extensive experience with due diligence matters and in-depth knowledge of regulatory data protection, orphan drug designations, clinical trial exemptions, and patent term extensions such as SPCs.
